Oxford Biomedica (LON:OXB) Given New GBX 800 Price Target at Deutsche Bank Aktiengesellschaft

Oxford Biomedica (LON:OXB) had its target price increased by Deutsche Bank Aktiengesellschaft from GBX 735 to GBX 800 in a research note issued to investors on Friday morning, MarketBeat Ratings reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Separately, Canaccord Genuity Group restated a “buy” rating and set a GBX 451 target price on shares of Oxford Biomedica in a research note on Tuesday, October 7th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Oxford Biomedica presently has a consensus rating of “Moderate Buy” and an average price target of GBX 606.40.

Oxford Biomedica Stock Down 1.2%

Shares of LON OXB opened at GBX 741.87 on Friday. The business has a 50-day moving average of GBX 627.54 and a two-hundred day moving average of GBX 547.44. The company has a market capitalization of £895.82 million, a price-to-earnings ratio of -20.48 and a beta of 1.09. Oxford Biomedica has a 1 year low of GBX 232.50 and a 1 year high of GBX 765. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67.

Insider Transactions at Oxford Biomedica

In other news, insider Heather Preston acquired 6,175 shares of the business’s stock in a transaction on Monday, October 20th. The stock was bought at an average price of GBX 593 per share, for a total transaction of £36,617.75. Corporate insiders own 34.83% of the company’s stock.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.